Reducing safety-related drug attrition: the use of in vitro pharmacological profiling
| العنوان: | Reducing safety-related drug attrition: the use of in vitro pharmacological profiling |
|---|---|
| المؤلفون: | Arun Sridhar, Jacques Hamon, Joanne Bowes, Gareth Waldron, Andrew J. Brown, Steven Whitebread, Wolfgang Jarolimek |
| المصدر: | Nature reviews. Drug discovery. 11(12) |
| سنة النشر: | 2012 |
| مصطلحات موضوعية: | Pharmacology, Drug, Knowledge management, Drug Industry, Drug-Related Side Effects and Adverse Reactions, business.industry, Drug discovery, Market Withdrawal, Collaborative knowledge, media_common.quotation_subject, General Medicine, medicine.disease, Risk Assessment, Biotechnology, Drug Discovery, medicine, Profiling (information science), Attrition, Business, Drug industry, media_common |
| الوصف: | In vitro pharmacological profiling is increasingly being used earlier in the drug discovery process to identify undesirable off-target activity profiles that could hinder or halt the development of candidate drugs or even lead to market withdrawal if discovered after a drug is approved. Here, for the first time, the rationale, strategies and methodologies for in vitro pharmacological profiling at four major pharmaceutical companies (AstraZeneca, GlaxoSmithKline, Novartis and Pfizer) are presented and illustrated with examples of their impact on the drug discovery process. We hope that this will enable other companies and academic institutions to benefit from this knowledge and consider joining us in our collaborative knowledge sharing. |
| تدمد: | 1474-1784 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::60147374fbba939fa1e41cb273d5aab8 https://pubmed.ncbi.nlm.nih.gov/23197038 |
| Rights: | CLOSED |
| رقم الانضمام: | edsair.doi.dedup.....60147374fbba939fa1e41cb273d5aab8 |
| قاعدة البيانات: | OpenAIRE |
كن أول من يترك تعليقا!